Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION Study of ONC201 after radiotherapy in newly diagnosed H3 K27M-mutant diffuse glioma
2022-502051-56-00Phase 3Authorised
- Sponsor
- Chimerix Inc.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in diffuse midline glioma (DMG) comparing ONC201 with Placebo (2 arms). Primary endpoint: Overall survival. Planned start Apr 2023; status: authorised.
02
Drugs
dordaviprone
03
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on 2022-502051-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502051-56-00.